Showing 411-420 of 3714 results for "".
- Morgan Dermatology to Expand with Financing from TD Bankhttps://practicaldermatology.com/news/morgan-dermatology-to-expand-with-financing-from-td-bank/2461058/Morgan Dermatology is expanding, thanks to a $1.38 million term loan and $5.26 million Commercial Real Estate Mortgage (CREM) from TD Bank and its Healthcare Practice Solutions Group (HPSG). The financing will enable Morgan Dermatology to relocate from its current 5,000-square-foot facility to a mo…
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://practicaldermatology.com/news/researchers-define-keys-to-recognizing-ocular-rosacea-1/2461052/A number of eye symptoms may be more common in patients with rosacea compared to those without the skin disease, but the presence of conjunctival telangiectases may be the eye symptom most closely associated with rosacea. Findings come from a study in which researchers evaluated the right eyes of …
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study reports that topical tapinarof cream, a new nonsteroidal cream for plaque psoriasis, is highly effective,” says study author Mark Lebwohl, MD, FAAD, …
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to two ye…
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supplemental New Drug Applicat…
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in adults w…
- ICYMI: ASA Honors Drs. Doris Day and Mark Lebwohl at Virtual Galahttps://practicaldermatology.com/news/icymi-asa-honors-drs-doris-day-and-mark-lebwohl-at-virtual-gala/2460521/Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year. Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellence in Dermatology Mentorship Aw…
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adults,…
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3 studies evaluating th…
- Pediatric Dermatologist Who Co-Founded Camp for Children Recognized for Carehttps://practicaldermatology.com/news/pediatric-dermatologist-who-co-founded-camp-for-children-recognized-for-care/2460153/The American Academy of Dermatology honored dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient with recessive dystrophic epidermolysis bullosa (RDEB). To support pediatric patients with isolating conditions like RDEB, Dr. Wiss, a dermatologist at UMass Me…